OncoFAP is a small molecule radiotracer with ultra high affinity for Fibroblast Activation Protein (FAP). The product is suitable for the non-invasive detection of a variety of metastatic solid tumors, as FAP is overexpressed in more than 90% of epithelial cancers (e.g., malignant breast, colorectal, ovarian, lung, skin, prostate and pancreatic cancers, as well as in some soft tissue and bone sarcomas).

The OncoFAP product consists of a (i) small organic ligand targeting FAP, (ii) an innovative spacer structure and (iii) a DOTAGA chelator. 

OncoFAP displays best-in-class performance both in vitro  and in vivo with the highest reported affinity to the FAP antigen. In preclinical models of cancer, the product has shown a very rapid and selective accumulation in the tumor mass with an exceptionally low kidney uptake.

Thanks to the pan-tumoral potential of the ligand, OncoFAP-68Ga is being developed for the imaging of different tumor entities.

  • OPTION 1: OncoFAP-68Ga has recently entered in a first-in-man imaging study in patients with advanced solid cancers.
  • OPTION 2: OncoFAP-68Ga has successfully been administered for the diagnosis of cancer patients with advanced solid malignancies (compassionate use).


The product is currently being used for compassionate treatment in patients before moving to a sponsored study

  • Millul et al. (2021) PNAS, 118, 16, e2101852118